Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Combination Midostaurin and Decitabine (MIDDAC) in Elderly Patients Newly Diagnosed With Acute Myeloid Leukemia and FLT3 Mutation

NCT02634827 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT02634827
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02634827 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Combination Midostaurin and Decitabine (MIDDAC) in Elderly Patients Newly Diagnosed With Acute Myeloid Leukemia and FLT3 Mutation
Lead sponsor
Mayo Clinic
Phase
Phase 2
Overall status
Terminated
Start date
December 30, 2015
Completion date
June 12, 2018
Enrollment
1 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia with flt3/itd mutation, acute myeloid leukemia with gene mutations, flt3 tyrosine kinase domain point mutation, secondary acute myeloid leukemia, untreated adult acute myeloid leukemia